Tang bm, eslick gd, nowson c, et al.

Dzhilki RL, Weinstein RS, Bellido T, et al. In 1999. Increased bone formation

to prevent apoptosis of osteoblasts with parathyroid hormone. J Clin Invest

, 104:439 BЂ "46. Johnell O, Kanis J, Gullberg G. 2001. Mortality, morbidity and assessment

fracture risk in men osteoporosis. Calcif tissue Int, 69:182 BЂ "4. M. Kaufman, Orwoll E, S Goemaere et al. In 2005. Teriparatide effects on

treatment and cessation of therapy. Osteoporos Int, 16:510 BЂ "6. Hosla S, S Amin, Orwoll E. 2008. Osteoporosis in men. Endocr Rev,

29:441 BЂ "64. Hosla S, Melton LJ 3, E. Atkinson and others. In 1998. How serum sex

men and women: a key role bioavailability of estrogen. J Clin Endokrinol

Metab, 83:2266 BЂ "74. Klotzbuecher CM, Ross PD, Landsman PB, et al. In 2000. Patients with previous >> << literature and statistical synthesis. In Costa Miner Res, 15:721 BЂ "39. Kukuljan S, bass-S, Salmon J, et al. In 2006. Does calcium-vitamin D3 fortiO ¬ Ѓ yet

randomized controlled trial. In Costa Miner Res, 21: S184. Courland ES, Kosman F, DJ McMahon et al. In 2000. Parathyroid hormone as

density and bone markers. J Clin Endokrinol Metab, 85:3069 BЂ "76. Courland ES, Heller SL, Diamond B, et al. In 2004. The importance of bisphospho-

wave [human parathyroid hormone glands (1BЂ "34)]. Osteoporos Int, 15:992 BЂ "7. Lau E, K Ong, Kurtz S, et al. In 2008. Mortality after the diagnosis of vertebral fracture

compression population health care. In the Coast

Joint Surg Am, 90:1479 BЂ "86. Leder BZ, LeBlanc KM, Shenfeld DA, et al. In 2003. The differential effect of androgens

and estrogen on bone turnover in normal men. J Clin

Endokrinol Metab, 88:204 BЂ "10. Lenart BA, Lorich DG, Lane JM. In 2008. Atypical fractures of the femur diaphysis >> << in postmenopausal women with alendronate. N Engl J Med,

358:1304 BЂ "6. Lips P. 2001. Vitamin D deO ¬ Ѓ efficiency and secondary hyperparathyroidism consequences.

Endocr Rev, 22:477 BЂ "501. Lord SR, Castell S, Corcoran J, et al. In 2003. Influence of group exercise at Lages

: randomized controlled trial. J Am Soc Geriatr, 51:1685 BЂ "92. Lyles KW, Colon-Emerik CS, Mahaziner JS and others. In 2007. Zoledronovoyi acid

and clinical fractures and mortality after hip fracture. N Engl J Med,

357:1799 BЂ "809. McCombs JS, Thibault P, McLaughlin, Miley C, et al. In 2004. Compliance

with drug therapy for the treatment and prevention of osteoporosis. Maturitas, 48:271 BЂ "87. 3 Melton LJ, Atkinson E. Cooper C, et al. In 1999. Fractures of the spine

predict future fractures. Osteoporos Int, 10:214 BЂ "21. Meryn S. 2005. Undertreatment of osteoporosis in men. Arch domestic Med,

165:241. Men PJ, Buaven G. 1997. Bone mineral density reO ¬, ECTS bone mass, and

degree of mineralization of bone: therapeutic implications. Bone, 21:373 BЂ "7. Michaelsson K, H Olofsson, Jensevik K, et al. In 2007. Leisure Physical Activity

and fracture risk in men. PLoS Med, 4: e199. Miller, D., Bilezikian JP, Diaz-Curiel M., et al. In 2007. The appearance

hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endokrinol Metab, 92:3535 BЂ "41. Miyakoshi N, Kasukawa Y, Linkhart TA, et al. In 2001. Evidence that anabolic effects of PTH >> << to bone require IGF-I in growing mice. Endocrinology

142:4349 BЂ "56. National Cancer Institute Surveillance Research Program. SEER Stat

version 6. A. 4. In 2001. Osteoporosis prevention, diagnosis and therapy

. JAMA, 285:785 BЂ "95. Nir R, Hayes, Rao et al. In 2002. Effects of parathyroid hormone, alendronate

, or as bone density in osteoporosis after menopause in women. In the Coast

Miner Res, 17: S135. Nir RM, Arnaud CD, Zanchetta JR, et al. In 2001. Influence of parathyroid

pausal women with osteoporosis. N Engl J Med, 344:1434 BЂ "41. Nevitt MC, Chen P, Kiel DP, et al. In 2006. Reduced risk of

treatment: results of meta-analysis. Osteoporos Int, 17:1630 BЂ "7. Nishida S, Yamaguchi, Tanizawa T, et al. In 1994. Increased bone formation

in the bone marrow. Bone, 15:717 BЂ "23. Oreffo RO, Mandi GR, Seyedin S. et al. In 1989. Activation of bone

received hidden TGF beta complex isolated osteoclasts. Biochem

Biophys Res Commun, 158:817 BЂ "23. Orwoll E, Oettinger M, S Weiss et al. In 2000. Alendronate for the treatment >> << osteoporosis in men. N Engl J Med, 343:604 BЂ "10. Orwoll ES, Klein R. 2001. Osteoporosis in men. Epidemiology, patho-physiology

and clinical characteristics. A: Mark R., Feldman D.

Kelsey, J. (eds.) Osteoporosis. 2nd ed. San - Diego: Academic Press. Orwoll E, Lambert LC, LM Marshall and others. In 2006. Testosterone lasix and estradiol >> << among older men. J Clin Endokrinol Metab, 91:1336 BЂ "44. Orwoll ES, Scheele WH, Paul S, et al. In 2003. Effect >> << teriparatide in osteoporosis. In Costa Miner Res, 18:09 BЂ "17. Quattrocchi E, Kourlas H. 2004. Teriparatide: a review. Clin Next, 26:841 BЂ "54. Reeve J, Men PJ, Parsons JA, et al. In 1980. Anabolic effect of human >> << osteoporosis: multicenter study. Br J Med, 280:1340 BЂ "4. Riggs BL, Melton LJ, Robbie RA et al. In 2008. Population-based

trabekulyarnoy bone loss in young and adult women and men. In Costa Miner

Res, 23:205 BЂ "14. Ringe JD, Faber H, P Farahmand et al. In 2006. EfO ¬ Ѓ advocacy ryzedronat

in men with primary and secondary osteoporosis: results of 1-year study. Rheumatol Int, 26:427 BЂ "31. Scane AC, Francis RM, Sutcliffe AM et al. In 1999. Case-control study of pathogenesis

and consequences of symptomatic vertebral fractures in men. Osteoporos Int, 9:91 BЂ "7. Seeman E. 2002. Pathogenesis of bone fragility in women and men. Lancet,

359:1841 BЂ "50. Silva MJ, Gibson LJ. In 1997. Modeling the mechanical behavior of vertebral trabecu-

LAR bone: influence of age changes in the microstructure. Bone, 21:191 BЂ "9. Stroup J, Kane MP, Abu-Baker AM. In 2008. Teriparatide in the treatment of osteoporosis >>. << Am J Health Syst Pharm, 65:532 BЂ "9. Stroup J, Kane MP Busch RS. In 2003. Pharmacist-run teriparatide clinic. Have

J Health Syst Pharm, 60:2247 BЂ "9. There CS, Heersche N., Murray TM, et al. In 1982. Parathyroid hormone

action: different effects of periodic and continuous management. Endocrinology, 110:506 BЂ "12. Tang BM, Eslick GD, Nowson C, et al. In 2007. Use of calcium or calcium in the com-

in people aged 50 years and older: results of meta-analysis. Lancet, 370:657 BЂ "66. Tinetti ME. In 2003. Clinical Practice. Preventing falls in elderly people. N Engl J Med, 348:42 BЂ "9. Wit R, Chan PC, McFarlane GD. In 2001. EfO Ѓ ¬ cisely and safety of vitamin D3

consumption exceeding the lowest observed adverse effects. Have

J Clin Nutr, 73:288 BЂ "94. Visekruna M, D Wilson, McKiernan FE. In 2008. Severely suppressed bone turnover

and atypical skeletal fragility. J Clin Endokrinol Metab,

93:2948 BЂ "52. .